Johnson & Johnson scored positive Phase 3 results for Talvey (talquetamab-tgvs) when paired with Darzalex Faspro (daratumumab and hyaluronidase-fihj), with data presented in the New England Journal of Medicine and at the European Hematology Association meeting. The combination reduced risk of disease progression or death and showed a significant reduction in mortality versus the standard regimen in relapsed or refractory multiple myeloma. J&J said the regimen cut risk of death by up to 53% after two years and reduced progression-or-death risk by up to 72%, positioning the data as evidence of superior progression-free survival in earlier-line disease. Talvey is a GPRC5D-targeting CD3 bispecific antibody approved for heavily pretreated patients. The company said it is now working with regulators to expand Talvey’s label in the U.S. and Europe, as it continues efforts to grow its blood-cancer franchise while other products face competitive pressure.